The first half of the year was announced in the first half of the year. From the point of the mid-term report card, listed companies in China by the national health insurance directory, two votes, health China 2030 dividend policy influence performance is good, such as health industry bon clue.
As of 17:00 on June 13, 1, 137 listed companies in the Shanghai and shenzhen stock markets announced the results of the 2017 semi-annual report, and 56 were listed in the pharmaceutical manufacturing industry. Of these, 48 pharmaceutical companies had a pre-happy record, accounting for 85.71 per cent.
Points section, published in 2017, a semi-annual performance forecast of the listed pharmaceutical companies, proprietary Chinese medicine sector has good performance, in addition to jia should pharmaceutical net profit is expected to contract slightly, other 22 proprietary Chinese medicine enterprises are from the same period a year earlier. This is due to the fact that in recent years, the influence of the state on the policy support of traditional Chinese medicine has been strengthened, and the development momentum of the integrated drug industry has been better.
It is worth noting that the company's net profit is expected to double in the middle of the year compared with the year before. Contrast in the first quarter, purple xin pharmaceutical (in the first quarter net profit of 35.2726 million yuan, up 231.99% from a year earlier), yongan pharmaceutical (in the first quarter net profit of 26.0375 million yuan, up 187.41% from a year earlier), wide reputation far (first-quarter net profit of 24.25 million yuan, an increase of 199.66%) in the first quarter net profit growth rates is larger, so the center daily news last quarter's growth advantage also understandable. However, Rhine biological (in the first quarter net profit of 12.9646 million yuan, rose to 22.28%) in the first quarter net profit is low, center daily news report to realize overhauling this is noteworthy, speculated that the reason may be due to the BT project contract has received the receivable and product information by the policy support of traditional Chinese medicine. Immortality biological (first-quarter net profit of 91.3061 million yuan, an increase of 49.63%) with higher net worth attention, its main product is the use of the rabies vaccine, freeze-dried live attenuated hepatitis a vaccine and so on six kinds of vaccines, among them, people use the rabies vaccine market share. In addition, the development of the vaccine technology transfer agreement with the institute of microbiology of the Chinese academy of sciences in May, the vaccine business is expected to go further in 2017.
56 pharmaceutical manufacturing industry listed company semi-annual report performance forecast
Source: Orient wealth network |
